IP Library Granted Patent US 9,481,654
Granted Patent B2
US 9,481,654 · App. 14/624,301 · Granted Nov 1, 2016

Compositions and methods for inhibition of the JAK pathway

Inventors: Hui Li (Santa Clara, CA); Ankush Argade (Foster City, CA); Kin Tso (San Francisco, CA); Sambaiah Thota (Fremont, CA); David Carroll (San Francisco, CA); Arvinder Sran (Fremont, CA); Robin Cooper (St. George Island, FL); Rajinder Singh (Belmont, CA); Somasekhar Bhamidipati (Foster City, CA); Vanessa Taylor (San Francisco, CA); Esteban Masuda (Menlo Park, CA)
Assignee: Rigel Pharmaceuticals, Inc.
C07D239/50A61K31/505A61K31/506A61K45/06C07D239/48C07D401/12C07D403/12C07D409/12C07D417/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,481,654
App. No.
14/624,301
Granted
Nov 1, 2016
Kind
B2
Abstract

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Claims (32)

1. A compound having a formula

or a pharmaceutically acceptable salt thereof, wherein:

p is 0, 1, 2 or 3;

q is 0, 1, 2 or 3;

X is selected from the group consisting of hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halo, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkynyl, and substituted cycloalkynyl;

Y is alk-SO 2 N(R 4 )R 5 or alk-N(R 4 )SO 2 R 5 ;

alk is selected from the group consisting of straight or branched chain C 1-6 alkylene group, cycloalkylene and substituted cycloalkylene;

each R 2 independently is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkynyl, substituted alkynyl, cycloalkynyl, substituted cycloalkynyl, alkynyloxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro, and halo;

or R 4 and one of R 2 together with the intervening atoms bound thereto form a heterocyclic or a substituted heterocyclic fused to the phenyl ring;

or R 5 and one of R 2 together with the intervening atoms bound thereto form a heterocyclic or a substituted heterocyclic fused to the phenyl ring;

each R 3 independently is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkynyl, substituted alkynyl, cycloalkynyl, substituted cycloalkynyl, alkynyloxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro, halo, and aminosulfonyl;

R 4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl and M + , wherein M + is a counterion selected from the group consisting of K + , Na + , Li + and + N(R 8 ) 4 , wherein R 8 is hydrogen or alkyl, and the nitrogen of —SO 2 N(R 4 )R 5 or —N(R 4 )SO 2 R 5 is N − ; and

R 5 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, amine, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and acyl; or

R 4 and R 5 together with the intervening atom or atoms bound thereto form a heterocyclic or a substituted heterocyclic group.

2. The compound of claim 1 wherein the compound has a formula

3. The compound of claim 2 , wherein alk is C 1-2 alkyl.

4. The compound of claim 3 , wherein X is halo, alkyl or haloalkyl.

5. The compound of claim 4 , wherein p is 0, 1, or 2 and R 2 is halo.

6. The compound of claim 5 , wherein q is 0, 1, or 2 and R 3 is alkyl.

7. The compound of claim 6 , wherein each of R 4 and R 5 independently is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkynyl, substituted alkynyl, acyl, and carboxyl ester; or R 4 and R 5 together with the nitrogen atom bound thereto optionally form —N═C(OR 9 ) 2 wherein each R 9 is independently an alkyl group.

8. The compound of claim 7 , wherein each of R 4 and R 5 is independently selected from the group consisting of hydrogen and acyl.

9. The compound of claim 2 , wherein the compound has a formula

10. The compound of claim 1 wherein the compound has a formula

11. The compound of claim 10 , wherein X is halo.

12. The compound of claim 11 , wherein X is fluoro.

13. The compound of claim 12 , wherein p is 0 and q is 0 or 1.

14. The compound of claim 12 , wherein q is 1 or 2 and R 3 is alkyl.

15. The compound of claim 12 , wherein alk is —CH 2 — and each of R 4 and R 5 independently is selected from the group consisting of hydrogen, alkyl, alkynyl, cycloalkyl and heterocyclic.

16. A method of inhibiting an activity of a JAK kinase, comprising contacting the JAK kinase with an amount of a compound according to claim 1 effective to inhibit an activity of the JAK kinase.

17. The method according to claim 16 comprising contacting in vitro a JAK3 kinase with an amount of a compound according to claim 1 effective to inhibit an activity of the JAK3 kinase.

18. A method of treating or preventing rheumatoid arthritis, comprising administering to a subject an effective amount of a compound according to claim 1 .

19. The method of claim 18 in which the compound is administered in combination with, or adjunctively to, a compound that inhibits Syk kinase with an IC 50 in the range of at least 10 μM.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2015
From: LI, HUI; ARGADE, ANKUSH; TSO, KIN; THOTA, SAMBAIAH; CARROLL, DAVID; SRAN, ARVINDER; COOPER, ROBIN; SINGH, RAJINDER; BHAMIDIPATI, SOMASEKHAR; TAYLOR, VANESSA; MASUDA, ESTEBAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 035025/0674 →
Continuity (4)
Continuation 11678488 · Feb 23, 2007
Provisional Application 60862166 · Oct 19, 2006
Provisional Application 60776636 · Feb 24, 2006
Related Publication 20150158824A1 · Jun 11, 2015